| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 66.588 | - | 155.390 | 294.823 | 350.784 | 400.611 | 470.965 | 583.374 | 574.975 | 576.695 |
| Total Income - EUR | 69.286 | - | 155.867 | 295.168 | 352.360 | 401.541 | 477.690 | 587.912 | 584.725 | 597.168 |
| Total Expenses - EUR | 71.526 | - | 113.451 | 211.888 | 288.891 | 327.103 | 373.232 | 462.891 | 449.872 | 480.041 |
| Gross Profit/Loss - EUR | -2.240 | - | 42.415 | 83.279 | 63.469 | 74.438 | 104.458 | 125.021 | 134.853 | 117.127 |
| Net Profit/Loss - EUR | -2.538 | - | 40.855 | 80.332 | 60.183 | 71.182 | 100.778 | 120.362 | 125.395 | 100.291 |
| Employees | 2 | - | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
Check the financial reports for the company - Pharmazone Innovative Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 52.576 | - | 43.753 | 2.310 | 30.437 | 31.990 | 20.132 | 9.559 | 2.347 | 2.986 |
| Current Assets | 29.666 | - | 41.122 | 197.627 | 124.328 | 171.384 | 237.215 | 289.013 | 294.259 | 307.530 |
| Inventories | 11.883 | - | 13.091 | 59.116 | 54.111 | 61.904 | 113.570 | 132.917 | 141.485 | 203.708 |
| Receivables | 12.727 | - | 19.315 | 93.313 | 30.342 | 55.275 | 28.046 | 44.008 | 45.844 | 37.845 |
| Cash | 5.056 | - | 8.715 | 45.197 | 39.875 | 54.205 | 95.598 | 112.088 | 106.929 | 65.976 |
| Shareholders Funds | -24.382 | - | 6.808 | 69.315 | 69.248 | 106.475 | 162.335 | 187.148 | 202.104 | 209.490 |
| Social Capital | 450 | - | 438 | 430 | 421 | 413 | 404 | 406 | 404 | 402 |
| Debts | 106.693 | - | 78.097 | 130.717 | 85.986 | 97.679 | 95.677 | 112.531 | 95.256 | 101.821 |
| Income in Advance | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4690 - 4690" | |||||||||
| CAEN Financial Year |
4690
|
|||||||||
Comments - Pharmazone Innovative Srl